Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Actuate Therapeutics Inc.
Bristol-Myers Squibb
AstraZeneca
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
Incyte Corporation
DEKA Biosciences
Eli Lilly and Company
Shanghai YingLi Pharmaceutical Co. Ltd.
NanOlogy, LLC
1Globe Biomedical Co., Ltd.
OHSU Knight Cancer Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sumitomo Pharma America, Inc.
University of Texas Southwestern Medical Center
Sumitomo Pharma America, Inc.
National Cancer Institute (NCI)
Chinese PLA General Hospital
National Cancer Institute (NCI)
New York Presbyterian Brooklyn Methodist Hospital
Gilead Sciences
Lumos Pharma
Fudan University
National Cancer Institute (NCI)
City of Hope Medical Center
Radiation Therapy Oncology Group
Rutgers, The State University of New Jersey
Seattle Cancer Treatment and Wellness Center